HIV protease inhibitors in early development

Expert Opinion on Investigational Drugs

Volumn 5, Issue 8, 1996, Pages 977-983

  Sham, H L ^a   Chen, X ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; KYNOSTATIN 272; LASINAVIR; MOZENAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PALINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; U 103017; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MARKETING; NONHUMAN; REVIEW;

EID: 0029768917     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.5.8.977     Document Type: Review

References (0)